Chemotherapy

New TAILORx Data, Published Today in JAMA Oncology, Add to Strong Evidence Base Reinforcing Unique Ability of Oncotype DX Breast Recurrence Score® Test to Guide Chemotherapy Treatment

Retrieved on: 
Monday, September 30, 2019
Medicine, RTT, Clinical medicine, Health, Breast cancer, Cancer, Chemotherapy, MammaPrint, Kathleen I. Pritchard

"TAILORx established that the Oncotype DX test definitively identifies the vast majority of women with early-stage breast cancer who receive no benefit from chemotherapy and the important minority for whom chemotherapy can be life-saving.

Key Points: 
  • "TAILORx established that the Oncotype DX test definitively identifies the vast majority of women with early-stage breast cancer who receive no benefit from chemotherapy and the important minority for whom chemotherapy can be life-saving.
  • NCCN also classified the Breast Recurrence Score test as the only test that is predictive of chemotherapy benefit.
  • The company's flagship product, the Oncotype DX Breast Recurrence Score test, is the only test that has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer.
  • Additionally, the Oncotype DX Breast DCIS Score test predicts the likelihood of recurrence in a pre-invasive form of breast cancer called DCIS.

Genentech Presents Positive Phase III Results for Tecentriq (Atezolizumab) in Combination With Platinum-based Chemotherapy in People With Previously Untreated Advanced Bladder Cancer

Retrieved on: 
Monday, September 30, 2019
Biotechnology, Health, Pharmaceutical, Oncology, Clinical medicine, Medicine, Carcinoma, Atezolizumab, Genentech, Cancer treatments, RTT, Chemotherapy, Transitional cell carcinoma, Transitional epithelium, Cancer, Small-cell carcinoma, the IMvigor130 study, bladder cancer, Tecentriq® (atezolizumab), Genentech in personalized cancer immunotherapy, Genentech

There appeared to be no worsening of tolerability with the addition of Tecentriq to chemotherapy compared with chemotherapy alone.

Key Points: 
  • There appeared to be no worsening of tolerability with the addition of Tecentriq to chemotherapy compared with chemotherapy alone.
  • All cause Grade 3-4 adverse events (AEs) were reported in 85% of people receiving Tecentriq plus chemotherapy compared with 86% of people receiving chemotherapy alone.
  • Treatment-related Grade 3-4 AEs were reported in 83% of people receiving Tecentriq plus chemotherapy compared with 81% of people receiving chemotherapy alone.
  • Tecentriq is a prescription medicine used to treat adults with:
    A type of bladder and urinary tract cancer called urothelial carcinoma.

Opdivo (nivolumab) Demonstrates Statistically Significant Overall Survival Benefit Versus Chemotherapy in Patients with Advanced Esophageal Cancer

Retrieved on: 
Monday, September 30, 2019
Biotechnology, Health, Pharmaceutical, Oncology, Cancer, Clinical medicine, Medicine, Lung cancer, Antineoplastic drugs, Cancer treatments, Breakthrough therapy, Bristol-Myers Squibb, Small-cell carcinoma, Non-small-cell lung carcinoma, Nivolumab, Chemotherapy

An exploratory analysis of patient-reported outcomes showed significant overall improvement in quality of life with Opdivo versus chemotherapy.

Key Points: 
  • An exploratory analysis of patient-reported outcomes showed significant overall improvement in quality of life with Opdivo versus chemotherapy.
  • Seven patients in the Opdivo arm had ongoing responses at data cutoff compared to two patients in the chemotherapy arm.
  • Fewer treatment-related adverse events (TRAEs) were reported with Opdivo versus chemotherapy, with a rate of 66% of any grade TRAEs for patients receiving Opdivo compared to 95% for patients receiving chemotherapy.
  • OPDIVO (nivolumab) is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy.

The global pharyngeal cancer market at a CAGR of over 6% during the forecast period

Retrieved on: 
Monday, September 30, 2019
RTT, Cancer, Medicine, Clinical medicine, Otorhinolaryngology, Oncology, Head and neck cancer, Chemotherapy, Pharyngeal

NEW YORK, Sept. 30, 2019 /PRNewswire/ -- Global Pharyngeal Cancer Market: About this market

Key Points: 
  • NEW YORK, Sept. 30, 2019 /PRNewswire/ -- Global Pharyngeal Cancer Market: About this market
    This pharyngeal cancer market analysis considers sales from targeted therapy and chemotherapy products.
  • Also, our global pharyngeal cancer market report looks at factors such as high-risk factors for pharyngeal cancer, increasing geriatric population, and increasing awareness of pharyngeal cancer.
  • Viral infections associated with the throat can lead to the development of throat cancer, including pharyngeal cancer.
  • Thus, such high-risk factors for pharyngeal cancer will lead to the expansion of the global pharyngeal cancer market at a CAGR of over 6% during the forecast period.

BiomX Presents In Vivo Data on Bacteriophage Delivery to Intra-Tumor Bacteria

Retrieved on: 
Monday, September 30, 2019
Cancer, Medicine, Clinical medicine, RTT, Antineoplastic drugs, Oncology, Colorectal cancer, Chemotherapy

BiomX's colorectal cancer program is targeting bacteria that are naturally present in tumors, with the aim to convert 'cold' tumors to 'hot' by releasing an immunostimulatory payload and eradicating tumor-protective bacteria.

Key Points: 
  • BiomX's colorectal cancer program is targeting bacteria that are naturally present in tumors, with the aim to convert 'cold' tumors to 'hot' by releasing an immunostimulatory payload and eradicating tumor-protective bacteria.
  • "Using synthetic biology, we can create phage therapies that exploit the co-existence of specific bacteria within cancerous tumors to induce a focused anti-tumor immune response.
  • "These results show early promise for our colorectal cancer program and for future targeting of bacteria in additional cancer types."
  • BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.

Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Statistically Significant Increase in Pathological Complete Response Versus Chemotherapy as Neoadjuvant Therapy in Early-Stage Triple-Negative Breast Cancer (TNBC)

Retrieved on: 
Sunday, September 29, 2019
FDA, Other Health, Pharmaceutical, Oncology, Women, Clinical trials, Science, Biotechnology, Consumer, Research, Health, Clinical medicine, Medicine, Cancer, Cancer treatments, Antineoplastic drugs, Oncology, Breakthrough therapy, Merck, Pembrolizumab, Adjuvant therapy, Neoadjuvant therapy, Chemotherapy, Triple-Negative Breast Cancer (TNBC), Merck

In the neoadjuvant phase, KEYTRUDA plus chemotherapy (n=401) resulted in a statistically significant increase in pathological complete response (pCR) versus chemotherapy (n=201), from 51.2% with neoadjuvant chemotherapy to 64.8% for neoadjuvant KEYTRUDA plus chemotherapy, in patients with early-stage TNBC (p=0.00055).

Key Points: 
  • In the neoadjuvant phase, KEYTRUDA plus chemotherapy (n=401) resulted in a statistically significant increase in pathological complete response (pCR) versus chemotherapy (n=201), from 51.2% with neoadjuvant chemotherapy to 64.8% for neoadjuvant KEYTRUDA plus chemotherapy, in patients with early-stage TNBC (p=0.00055).
  • In the PD-L1 CPS 1 subgroup, the rates of pCR were 68.9% for neoadjuvant KEYTRUDA plus chemotherapy (n=334) versus 54.9% for neoadjuvant chemotherapy (n=164).
  • In the PD-L1 CPS
  • TRAEs resulting in discontinuation of any treatment occurred in 23.3% of patients receiving KEYTRUDA plus chemotherapy and 12.3% of patients receiving chemotherapy.

Final Study Results Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination Treatment in Advanced Endometrial Cancer Presented at ESMO 2019 Congress

Retrieved on: 
Sunday, September 29, 2019
Research, Clinical trials, Biotechnology, Pharmaceutical, Health, Oncology, Science, Cancer treatments, Clinical medicine, Antineoplastic drugs, Chemotherapy, Breakthrough therapy, Merck, Pembrolizumab, Endometrial Cancer, LENVIMA® (lenvatinib) Capsules, 10 mg and 4 mg, Eisai

In Sept. 2019, the Australian Therapeutic Goods Administration (TGA) and Health Canada also approved the combination of KEYTRUDA plus LENVIMA for the treatment of advanced endometrial carcinoma.

Key Points: 
  • In Sept. 2019, the Australian Therapeutic Goods Administration (TGA) and Health Canada also approved the combination of KEYTRUDA plus LENVIMA for the treatment of advanced endometrial carcinoma.
  • In the total study population (N=108), treatment-related TEAEs occurred in 97.2% of patients (N=105) who received the KEYTRUDA plus LENVIMA combination.
  • In the total study population (N=108), immune-related TEAEs occurred in 57.4% of patients (N=62) who received the KEYTRUDA plus LENVIMA combination.
  • Immune-related TEAEs (Grade 3-4) occurred in 13% of patients (N=14) who received the KEYTRUDA plus LENVIMA combination.

ImmunoGen Presents Full Data from Phase 3 FORWARD I Study of Mirvetuximab Soravtansine in Ovarian Cancer at ESMO

Retrieved on: 
Sunday, September 29, 2019
Oncology, Health, Clinical trials, Pharmaceutical, Biotechnology, Organic compounds, RTT, Medicine, Clinical medicine, Oncology, Cancer treatments, Antineoplastic drugs, Doxorubicin, Teratogens, Chemotherapy, Paclitaxel, PEGylation

The encouraging data from FORWARD I suggest the potential for a significant improvement over single-agent chemotherapy in the FR high population and I look forward to the continued development of mirvetuximab for these patients in the upcoming Phase 3 study.

Key Points: 
  • The encouraging data from FORWARD I suggest the potential for a significant improvement over single-agent chemotherapy in the FR high population and I look forward to the continued development of mirvetuximab for these patients in the upcoming Phase 3 study.
  • The FORWARD I Phase 3 trial randomized 366 patients 2:1 to receive either mirvetuximab or the physician's choice of single-agent chemotherapy (pegylated liposomal doxorubicin, topotecan, or weekly paclitaxel).
  • Eligibility criteria included patients with platinum-resistant ovarian cancer that expressed medium or high levels of FR, who had been treated with up to three prior regimens.
  • Previous studies with mirvetuximab have used a PS2+ scoring method to assess tumor samples for FR expression to determine eligibility.

LYNPARZA (olaparib) Improved the Time Women Lived Without Disease Progression to 22 Months in the Broad Population and 37 Months in HRD-positive Patients as 1st-line Maintenance Treatment with Bevacizumab for Newly Diagnosed Advanced Ovarian Cancer

Retrieved on: 
Saturday, September 28, 2019
Biotechnology, FDA, General Health, Health, Pharmaceutical, Oncology, Genetics, Clinical trials, Clinical medicine, Medicine, Cancer, Cancer treatments, RTT, Oncology, Angiogenesis inhibitors, Genentech, Bevacizumab, Olaparib, Ovarian cancer, Chemotherapy, PAOLA-1, LYNPARZA, ovarian cancer, homologous recombination deficiency (HRD), BRCA Mutations, the AstraZeneca and Merck strategic oncology collaboration, AstraZeneca in Oncology, AstraZeneca

Overall Grade 3 or above adverse events (AEs) were 57% for LYNPARZA added to bevacizumab and 51% for bevacizumab alone.

Key Points: 
  • Overall Grade 3 or above adverse events (AEs) were 57% for LYNPARZA added to bevacizumab and 51% for bevacizumab alone.
  • AEs led to dose interruption in 54% of patients on LYNPARZA while 20% of patients discontinued treatment.
  • LYNPARZA is currently approved as 1st-line maintenance treatment in women with somatic and germline BRCA-mutated advanced ovarian cancer following response to platinum-based chemotherapy.
  • For 1st-line maintenance in advanced ovarian cancer and the metastatic breast cancer setting, physicians should select patients for therapy based on an FDA-approved companion diagnostic.

LYNPARZA® (olaparib) Phase 3 PAOLA-1 Trial Significantly Increased Progression-Free Survival as First-Line Maintenance Treatment with Bevacizumab for Newly-Diagnosed Advanced Ovarian Cancer

Retrieved on: 
Saturday, September 28, 2019
Research, Clinical trials, Biotechnology, Pharmaceutical, Health, Oncology, Science, Clinical medicine, Medicine, Cancer, RTT, Cancer treatments, Oncology, Bevacizumab, Genentech, Ovarian cancer, PARP inhibitor, Olaparib, Chemotherapy, PAOLA-1, LYNPARZA® (olaparib), Ovarian Cancer, Homologous Recombination Deficiency (HRD), GINECO, ENGOT, GCIG, the AstraZeneca and Merck Strategic Oncology Collaboration, Merck

Overall Grade 3 or above (AEs) were 57% for LYNPARZA added to bevacizumab and 51% for bevacizumab alone.

Key Points: 
  • Overall Grade 3 or above (AEs) were 57% for LYNPARZA added to bevacizumab and 51% for bevacizumab alone.
  • It is approved in the U.S. as first-line maintenance treatment in BRCAm advanced ovarian cancer following response to platinum-based chemotherapy.
  • LYNPARZA is the only PARP inhibitor with positive Phase 3 trials in four different cancer types.
  • Ovarian cancer the eighth most common cause of death from cancer in women worldwide, with a five-year survival rate of approximately 19%.